4.30.2014 | Forbes
By Steve Brozak
Business is war and nothing is more illustrative of that point than a healthy cycle of M&A activity. Amid a wave of healthcare transactions, Pfizer, one of the world’s largest pharmaceutical companies, announced a $100 billion bid for the British pharmaceutical company AstraZeneca. What if this were the least bad choice for Pfizer in an increasingly challenging business environment? Pfizer, like other large pharmaceutical companies, is struggling. The blockbuster patent cliff has left the company with greatly diminished revenue and has endangered earnings per share. In 2010, Pfizer revenue was more than $65 billion while in 2013 revenue declined to $51.6 billion, a decrease of more than 20% in three years. For the full article, please click here.
